Feature | December 09, 2014

Risk-based Breast Cancer Screening Misses Cancers in Women in Their Forties

Study finds basing screenings on family history and dense breast tissue can miss more than 75 percent of cancers in women in their forties

RSNA 2014, risk-based cancer screenings, mammography

Bilateral MLO views from screening mammography.

RSNA 2014, risk-based cancer screenings, mammography

A spot magnification view demonstrates an irregular spiculated mass with associated calcifications in the upper outer left breast.

RSNA 2014, risk-based cancer screenings, mammography

This is a screening mammogram demonstrating calcifications in the upper outer left breast. Bilateral cranio-caudal views shown here.

December 9, 2014 — A study of breast cancers detected with screening mammography found that strong family history and dense breast tissue were commonly absent in women between the ages of 40 and 49 diagnosed with breast cancer. Results of the study were presented at the annual meeting of the Radiological Society of North America (RSNA).

"Screening recommendations for this age group continue to be debated," said Bonnie N. Joe, M.D., Ph.D., associate professor in residence and chief of women's imaging at University of California, San Francisco (UCSF). "Recent publications have suggested risk-based screening based on family history and breast density. However, our study shows that this approach would miss a significant percentage of invasive cancers and could potentially be dangerous."

The retrospective study, conducted at UCSF, included 136 women between the ages of 40 and 49 with breast cancer identified by screening mammography between 1997 and 2012. Symptomatic patients undergoing diagnostic mammography and those with a personal history of breast cancer were excluded from the study. Patient family history, breast density, type of malignancy, lymph node status and tumor receptor status were recorded.

"Notably, we found that almost 90 percent of the invasive cancers we would have missed using risk-based triage had positive receptor status, meaning they were very treatable and worth finding early," Joe said.

Of the 136 breast cancer cases identified, 50 percent were diagnosed as invasive, and 50 percent were diagnosed as ductal carcinoma in situ (DCIS), an early noninvasive form of breast cancer, although 88 percent of DCIS cases were intermediate or high grade.

A very strong family history was absent in 90 percent of patients, and extremely dense breast tissue was absent in 86 percent. Seventy-eight percent of patients had neither strong family history nor extremely dense breasts, including 79 percent of the cases of invasive disease.

"Our results show that by exclusively using a risk-based approach to screening mammography, we could potentially miss more than 75 percent of breast cancers in women in their 40s, thereby eliminating most of the survival benefit from screening mammography that has been previously shown in randomized controlled trials," Joe said.

She urges proponents of risk-based screening to continue research to find more effective means of risk-based triage.

Routine annual screening mammography has traditionally been recommended by organizations such as the American Cancer Society (ACS) and the American Medical Association (AMA) for all women beginning at age 40. In 2009, the United States Preventive Services Task Force (USPSTF) issued controversial new guidelines recommending screening with mammography every two years beginning at age 50.

"Based on our current knowledge and evidence shown in previous trials, it is still safest to get annual mammograms starting at age 40 in order to maximize the survival benefit of screening mammography," Joe said.

For more information: www.radiologyinfo.org

Related Content

Volpara Solutions to Showcase VolparaEnterprise Live! at RSNA
News | Mammography | October 16, 2017
Volpara Solutions will introduce VolparaEnterprise Live!, a mammography quality control tool, at the 2016 Radiological...
TMIST Mammography Study Opens Enrollment
News | Mammography | October 16, 2017
The Tomosynthesis Mammographic Imaging Screening Trial (TMIST), the first randomized trial to compare two types of...
National Breast Center Founder Names Top Three Innovations in Breast Cancer Treatment
News | Women's Health | October 11, 2017
In 2017, invasive breast cancer will be diagnosed in about 252,710 women and 2,470 men in the U.S. and remains the...
CyberKnife System Provides Excellent Long-Term Control of Low-Risk Prostate Cancer
News | Stereotactic Body Radiation Therapy (SBRT) | October 10, 2017
Accuray Inc. announced that data from a prospective study of 230 men with low-risk prostate cancer showed 98.4 percent...
News | Image Guided Radiation Therapy (IGRT) | October 10, 2017
Elekta announced that members of the Elekta MR-linac Consortium reported data related to the advancement of the company...
Stanford Trial Demonstrates Accuracy of Accuro Image-Guided Epidural System
News | Ultrasound Imaging | October 09, 2017
October 9, 2017 — A clinical trial conducted at Stanford University Medical Center...
News | Brachytherapy Systems | October 05, 2017
External researchers presented new clinical data supporting the use of iCAD’s Xoft Axxent Electronic Brachytherapy (eBx...
Majority of Recurrent Prostate Cancer Patients' Treatment Plan Changed Following Fluciclovine 18F PET/CT
News | Prostate Cancer | October 04, 2017
Blue Earth Diagnostics recently announced the results of a pre-planned interim analysis from an investigational...
Joint Venture Partnership Opening 16 New Breast Screening Sites in Texas
News | Breast Imaging | October 04, 2017
HCA Healthcare Gulf Coast Division and Solis Mammography have entered into a joint venture agreement to make breast...
International Trial Confirms Safety, Effectiveness of High-Dose Brachytherapy Plus Pelvic Radiation for Cervical Cancer
News | Brachytherapy Systems, Women's Healthcare | October 04, 2017
Findings from a new multicenter, international clinical trial confirm the effectiveness of high-dose brachytherapy or...
Overlay Init